Clinical Trials Browser

Phase 3 × Interventional × Plasma cell × Clear all

NCT05519085 2026-05-27

SUCCESSOR-1

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT06158841 2026-05-27

CERVINO

Phase 3 Recruiting

Multiple Myeloma

NCT07555938 2026-05-27

CEVOLUTION

Phase 3 Recruiting

Multiple Myeloma

NCT05184088 2026-05-26

CArdiag

Phase 3 Active not recruiting

Immunoglobulin Light-chain Amyloidosis, Amyloid Neuropathies, Familial

NCT00734877 2026-05-22

TT4B

Phase 3 Active not recruiting

Multiple Myeloma

NCT06152575 2026-05-22

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Phase 3 Recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07138209 2026-05-22

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT06980480 2026-05-18

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

Phase 3 Recruiting

Multiple Myeloma

NCT07285239 2026-05-18

PrE1005

Phase 3 Not yet recruiting

Multiple Myeloma

NCT03937635 2026-05-15

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Phase 3 Recruiting

Smoldering Multiple Myeloma

NCT04566328 2026-05-15

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Phase 3 Recruiting

Multiple Myeloma

NCT05623020 2026-05-14

MagnetisMM-6

Phase 3 Recruiting

Multiple Myeloma

NCT03844048 2026-05-13

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Phase 3 Active not recruiting

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06615479 2026-05-13

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT03891914 2026-05-12

MYELOCHOL

Phase 3 Completed

Multiple Myeloma

NCT06182774 2026-05-12

Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma

Phase 3 Recruiting

Multiple Myeloma

NCT07579234 2026-05-12

A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT07582432 2026-05-12

SIGMA

Phase 3 Recruiting

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04181827 2026-05-11

CARTITUDE-4

Phase 3 Active not recruiting

419 enrolled 10 charts

Multiple Myeloma

NCT06963216 2026-05-11

A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis

Phase 3 Recruiting

Immunoglobulin Light-chain Amyloidosis, Blood Coagulation Disorders, Factor X Deficiency, Hematologic Diseases, Hemorrhagic Disorders

NCT07518186 2026-05-11

TRIlogy-5

Phase 3 Not yet recruiting

Multiple Myeloma

NCT03901963 2026-05-08

AURIGA

Phase 3 Active not recruiting

200 enrolled 12 charts

Multiple Myeloma

NCT04923893 2026-05-08

CARTITUDE-5

Phase 3 Active not recruiting

Multiple Myeloma

NCT05083169 2026-05-08

MajesTEC-3

Phase 3 Active not recruiting

587 enrolled 1 FDA

Multiple Myeloma

NCT05438043 2026-05-08

A Study of Daratumumab

Phase 3 Recruiting

Multiple Myeloma

NCT05552222 2026-05-08

MajesTEC-7

Phase 3 Recruiting

Multiple Myeloma

NCT07258511 2026-05-08

TRIlogy-4

Phase 3 Recruiting

Multiple Myeloma

NCT07569757 2026-05-08

Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma

Phase 3 Not yet recruiting

Multiple Myeloma

NCT06413498 2026-05-07

iMMagine-3

Phase 3 Recruiting

Multiple Myeloma

NCT06022939 2026-05-06

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

Phase 3 Recruiting

Immunoglobulin Light-chain Amyloidosis

NCT05020236 2026-05-05

MAGNETISMM-5

Phase 3 Recruiting

Multiple Myeloma

NCT03319667 2026-05-04

IMROZ

Phase 3 Active not recruiting

475 enrolled 1 FDA

Multiple Myeloma

NCT01169337 2026-05-01

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Phase 3 Active not recruiting

226 enrolled 16 charts

Smoldering Multiple Myeloma

NCT01231412 2026-04-30

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

Phase 3 Completed

174 enrolled 12 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Waldenstrom Macroglobulinemia, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07391657 2026-04-30

DURGA-4

Phase 3 Recruiting

Multiple Myeloma

NCT00114101 2026-04-29

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Phase 3 Active not recruiting

460 enrolled 11 charts

Smoldering Multiple Myeloma, Multiple Myeloma

NCT00602641 2026-04-29

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 3 Active not recruiting

306 enrolled 12 charts

Multiple Myeloma

NCT04246047 2026-04-23

DREAMM 7

Phase 3 Active not recruiting

494 enrolled 10 charts 1 FDA

Multiple Myeloma

NCT06868654 2026-04-23

DREAMM 7

Phase 3 Active not recruiting

72 enrolled 10 charts

Multiple Myeloma

NCT06868667 2026-04-23

DREAMM 7

Phase 3 Active not recruiting

24 enrolled 10 charts

Multiple Myeloma

NCT03823534 2026-04-22

Post-Op Pain Control for Prophylactic Intramedullary Nailing.

Phase 3 Recruiting

LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Pain, Pain, Postoperative

NCT06679101 2026-04-22

DREAMM-10

Phase 3 Recruiting

Multiple Myeloma

NCT05317416 2026-04-16

MagnetisMM-7

Phase 3 Active not recruiting

Hematologic Diseases, Multiple Myeloma

NCT03301220 2026-04-13

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

Phase 3 Active not recruiting

390 enrolled 12 charts 1 FDA

Smoldering Multiple Myeloma

NCT05455320 2026-04-13

MonumenTAL-3

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT05572515 2026-04-13

MajesTEC-9

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT03652064 2026-04-08

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Phase 3 Active not recruiting

395 enrolled 11 charts 1 FDA

Multiple Myeloma

NCT03993912 2026-04-07

IFM2017_03

Phase 3 Active not recruiting

Multiple Myeloma

NCT04512235 2026-04-07

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

Phase 3 Active not recruiting

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT00430365 2026-04-06

IFM2005-02

Phase 3 Completed

Neoplasms, Plasma Cell